Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/202031
Title: | A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer |
Author: | Sampayo Cordero, Miguel Miguel Huguet, Bernat Malfettone, Andrea López Miranda, Elena Gion, María Abad Adán, Elena Alcalá López, Daniel Pérez Escuredo, Jhudit Pérez García, José Manuel Llombart Cussac, Antonio Cortés, Javier |
Keywords: | Càncer de mama Tractament adjuvant del càncer Diagnòstic Breast cancer Adjuvant treatment of cancer Diagnosis |
Issue Date: | 11-Jul-2023 |
Publisher: | Frontiers Media SA |
Abstract: | De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized trials are commonly used to investigate de-intensified regimens with similar efficacy to that of standard regimens but with fewer adverse effects (ESMO evidence tier A). In cases where it is not feasible to recruit the number of patients needed for a randomized trial, single-arm prospective studies with a hypothesis of non-inferiority can be conducted as an alternative. Single-arm studies are also commonly used to evaluate novel treatment strategies (ESMO evidence tier B). A single-arm design that includes both non-inferiority and superiority primary objectives will enable the ranking of clinical activity and other parameters such as safety, pharmacokinetics, and pharmacodynamics data. Here, we describe the statistical principles and procedures to support such a strategy. The non-inferiority margin is calculated using the fixed margin method. Sample size and statistical analyses are based on the maximum likelihood method for exponential distributions. We present example analyses in metastatic and adjuvant settings to illustrate the usefulness of our methodology. We also explain its implementation with nonparametric methods. Single-arm designs with non-inferiority and superiority analyses are optimal for proof-of-concept and de-escalation studies in oncology. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2023.1048242 |
It is part of: | Frontiers in Oncology, 2023, vol. 13 |
URI: | http://hdl.handle.net/2445/202031 |
Related resource: | https://doi.org/10.3389/fonc.2023.1048242 |
ISSN: | 2234-943X |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fonc-13-1048242.pdf | 406.9 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License